Trial Profile
A multi-centre, double blind, placebo controlled, prospective study to assess safety and efficacy of orally administered killed whole cell nontypeable Haemophilus influenzae (NTHi) HI-1-164 in preventing episodes of acute bronchitis in patients with moderate to severe airway disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jun 2016
Price :
$35
*
At a glance
- Drugs HI 164 (Primary)
- Indications Acute bronchitis; Chronic obstructive pulmonary disease; Haemophilus infections
- Focus Therapeutic Use
- Sponsors Bioxyne
- 01 Dec 2009 Results reported in Chest.
- 08 Jun 2009 New trial record